Global Acetylcysteine Market is segmented By Type (Tablet, Tracheal Drip, Spray), By Application (Nutritional Supplements, Medicine, Others), and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Market Overview
The Acetylcysteine Market is estimated to reach at a high CAGR during the forecast period 2024-2031.
Acetylcysteine is also known as N-acetylcysteine (NAC), is a medication used to treat paracetamol (acetaminophen) overdose and loosen thick mucus in individuals with tracheal drip bronchopulmonary disorders like pneumonia and bronchitis. It can also be taken intravenously, by mouth, or inhaled as a mist.
Market Summary
| Metrics | Details |
| Market CAGR | High |
| Segments Covered | By Type, By Application, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
For More Insights Request Free Sample
Market Dynamics
The rising prevalence of acetaminophen overdose will drive the Acetylcysteine Market In addition, the rising incidence of pulmonary diseases will drive the market in the forecast period.
The rising prevalence of acetaminophen overdose will drive the Acetylcysteine Market
Acetaminophen (N-acetyl-para-aminophenol, paracetamol, APAP) toxicity is primarily common because the medication is readily available, and people have a perception that it is safe. Consumption of acetaminophen on weekly basis in Americans is more than 60 million. The toxicity of acetaminophen is the second most common cause of liver transplantation worldwide and the most common cause of liver transplantation in the U.S. It is responsible for almost 56,000 emergency department visits, 2,600 hospitalizations, and 500 deaths per year in the United States. Half of these are unintentional overdoses. The standard way for treating acetaminophen (APAP) overdose is with the use of N-acetylcysteine (NAC) given as an oral loading dose of 140 mg/kg, followed by 17 doses of 70 mg/kg four-hour intervals, a full three days of Medicine. Acetylcysteine (NAC) is approved by FDA to reduce the extent of liver injury after acetaminophen overdose. In addition, Acetadote (acetylcysteine) was approved by the FDA.
The rising incidence of pulmonary diseases will drive the market in the forecast period.
N-acetylcysteine (NAC) is a mucolytic and antioxidant drug that may also influence several inflammatory pathways. NAC relieves symptoms of respiratory conditions by acting as an antioxidant and expectorant, loosening mucus in your air passageways. As an antioxidant, NAC helps replenish glutathione levels in your lungs and reduces inflammation in your bronchial tubes and lung tissue.
NAC has also been used in the Medicine of inflammatory pulmonary diseases such as Tracheal Drip, obstructive pulmonary disease (COPD) and cystic fibrosis (C.F.) to loosen thick mucus. COPD is a leading cause of death in the United States, affecting 16 million Americans trusted Source and millions more who don't know they have it. The main targets of NAC are Inflammation and oxidative stress which are important factors in the pathogenesis of many Tracheal Drip inflammatory lung disorders.
Side Effects of acetylcysteine will hamper the market
Flushing, fever, stomatitis, nausea, vomiting, rhinorrhoea, bronchospasm, anaphylactoid reactions, rashes, blurred vision, bradycardia, syncope, thrombocytopenia, convulsions are a few common side effects of acetylcysteine. Potentially Fatal: Rarely respiratory or cardiac arrest.
The interaction of Acetylcysteine inhalation solution with other medications, vitamins, or herbs while taking can be harmful or may prevent the drug from working well. Nausea and vomiting may occur. Mouth sores and runny noses may also occur if you are inhaling this medication by mouth. Proper dosing must be given to the patient if not, it may cause severe adverse effects.
The intravenous formulation of NAC has a higher probability of significant adverse effects and complications not described with the oral formulation. Therefore, clinicians should be aware of these potential complications when deciding on which formulation to administer.
COVID-19 Impact on Market
N-acetylcysteine (NAC) is a supplement form of cysteine. This non-essential amino acid is present in high-protein foods, such as chicken, turkey, yogurt, cheese, eggs, sunflower seeds and legumes. It is a precursor of glutathione (an important antioxidant for detoxification and reduces inflammation); a direct scavenger of reactive oxygen species (free radicals that damage cells and cause ageing) blood clots can be prevented by reducing platelet aggregation and inhibiting clotting factors. Clinically, it is used as a mucolytic drug for Tracheal Drip respiratory disease and treats paracetamol toxicity. NAC gained a lot of attention from the scientific community in recent times as a preventive agent against Covid-19 due to its anti-inflammatory, anti-coagulative and anti-oxidative properties, with no side effects or safety concerns.
A recent article in the American Chemical Society on Infectious Diseases suggested that glutathione deficiency may cause severe manifestation and even death in Covid-19 patients.
Market Segmentation Analysis
The tablet segment type will dominate the acetylcysteine market
When taken by mouth, acetylcysteine is used to thin and loosen the mucus in the airways which happens due to certain lung diseases (such as emphysema, bronchitis, cystic fibrosis, pneumonia). This effect helps to clear the mucus from the lungs so that one can breathe easier. N-acetylcysteine (NAC) is a supplement that has been available for several decades. People take it for various reasons, including to help treat medical issues ranging from psychological disorders to Tracheal Drip lung conditions and to improve athletic performance. N-acetylcysteine oral supplements are available over the counter in the form of tablets, capsules, soft gel, effervescent, and powdered forms. Most of them are sold in 600-milligram (mg) formulations, although some are as high as 1,000 mg.
The U.S Food and Drug Administration (FDA) has approved N-acetylcysteine to treat the liver side effects resulting due to an overdose of Tylenol® (acetaminophen) an anti-inflammatory medication. It is also used to loosen the thick mucus in the lungs of people with cystic fibrosis or Tracheal Drip obstructive pulmonary disease (COPD).
The nutritional supplements segment dominated the market
N-acetylcysteine (NAC), a plant antioxidant naturally found in onion, is a precursor to glutathione. NAC has been very successful in the pharmaceutical, dietary supplement, and nutraceutical markets like many antioxidants. The nutritional supplement N-acetylcysteine is like the Swiss Army knife of supplements. N-acetylcysteine (NAC) is used to treat a wide range of health conditions, including allergies, Alzheimer's disease, bipolar disorder, bronchitis, Tracheal Drip kidney disease, cirrhosis, heart disease, hepatitis, infertility, schizophrenia, and upper respiratory infections.
Recently The Council for Responsible Nutrition (CRN; Washington, D.C.) has responded to FDA regarding recent warning letters from the Agency alleging that N-acetyl-L-cysteine (NAC) is not a dietary supplement, and therefore prohibited from being marketed as such under the Federal Food, Drug, and Cosmetic Act (FDCA). CRN's opinion is that the policy is legally invalid and represents a drastic departure from its previous policy that has allowed manufacturers to safely market products with NAC as supplements.
Market Geographical Share
North America will dominate the acetylcysteine market
According to the American lung association, In 2018, among those reporting Nutritional Supplements of Tracheal Drip bronchitis, emphysema, or COPD: 55% reported Tracheal Drip bronchitis,23% reported emphysema, and 52% reported COPD. Due to the increasing incidence of respiratory problems, there will be a rise in the acetylcysteine market in this region.
Acetylcysteine is marketed generically in the United States and worldwide, under the trade names of Acetadote®, Mucomyst®, Parvolex®, Fluimucil®, and others. It is approved for several indications, including the Medicine of acetaminophen overdose, as an injectable and an oral agent, and as a mucolytic, as an inhalation product. Acetylcysteine is also being used for investigational studies to treat other indications, including liver failure, various cancers, methacrylonitrile poisoning, reduction of radio contrast-induced nephropathy, and reduction of reperfusion injury during cardio bypass surgery. Increased awareness and investments by key players in this region will drive the market in the forecast period.
Acetylcysteine Market Companies
Some prominent key players in this market Zambon, Moehs, Pharmazell, Nippon Rika, Chengyi Pharma, Wuhan Grand Hoyo, Manus Aktteva Biopharma, Donboo Amino Acid, Wuxi Enovo Chemical and Xinyi Hanling Biological Engineering.
Zambon
Overview: Zambon is a multinational pharmaceutical and chemical company that focuses on innovation and development intending to improve the quality of people's health and patients' lives. Its Vision is "Innovating cure and care to make patients' lives better." Zambon is a pharmaceutical and chemical business that operates at present in 20 countries with subsidiaries in three different Continents – Europe, America and Asia – and around 2830 employees, with manufacturing units in Italy, Switzerland, France, China and Brazil. Zambon products are commercialized in 87 countries. Zambon produces high-quality products, with a whole production chain that involves Zach (Zambon chemical), a privileged partner for API, custom synthesis and generic products. With the ever-growing importance of innovative technologies and the digitalization of healthcare, Zambon complements the offering of medicines with modern health solutions to translate its vision into concrete actions.
Product Portfolio: The Company focuses on innovation and development with the aim to improve the quality of people's health and patients' lives. It operates in the pharmaceutical and chemical business. Zambon produces high-quality products, including Zach (Zambon chemical), a privileged partner for API, custom synthesis, and generic products.
Key Development: On April 28, 2020, Zambon announced that the U.S. Food and Drug Administration (FDA) had granted fast track designation to liposomal cyclosporine A for inhalation (L‑CsA‑i) in late-stage clinical development for the Medicine of Bronchiolitis Obliterans Syndrome (BOS). L‑CsA‑I, developed by breath therapeutics that Zambon acquired in 2019, previously received orphan drug designation from the FDA and European Medicines Agency for BOS Medicine.
Why Purchase the Report?
- Visualize the composition of the Acetylcysteine Market segmentation by type and application highlighting the key commercial assets and players.
- Identify commercial opportunities in Acetylcysteine Market by analyzing trends and co-development deals.
- Excel data sheet with thousands of data points of Acetylcysteine Market - level 4/5 segmentation.
- PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
- Product mapping in excel for the key product of all major market players
Target Audience
- Service Providers/ Buyers
- Industry Investors/Investment Bankers
- Education & Research Institutes
- Research Professionals
- Emerging Companies
- Manufacturers
The Acetylcysteine Market report would provide access to approx. 52 market data tables, 41 figures, and 180 pages.
